Floryne O. Buishand

Dr. Floryne O. Buishand

Queen Mother Hospital for Animals, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire AL9 7TA, United Kingdom
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
Floryne O. BuishandFloryne O. Buishand
Floryne O. Buishand
The most common pancreatic tumour in dogs is the insulinoma. Canine insulinomas are considered to be malignant in more than 95% of the cases because they almost always tend to metastasise. The diagnosis of an insulinoma requires the demonstration of the simultaneous occurrence of hypoglycaemia and blood insulin levels that are within or above the high end of the reference interval. The staging of canine insulinomas is preferably conducted by contrast-enhanced computed tomography. In general, surgical treatment is the most effective because of it results in long survival times, but many dogs also require medical treatment at some point. The prognosis of canine insulinomas is guarded as clinical hypoglycaemia almost always returns due to metastasis or tumour regrowth. This review aims to provide a summary and update the current recommendations in the veterinary literature for the diagnosis, treatment and prognostication of canine insulinomas.

1 January 2018 in Veterinary Quarterly
Verified
Journal Article
Open access
Floryne O. BuishandFloryne O. Buishand
Floryne O. Buishand
FGFederico R. Vilaplana Grosso
Federico R. Vilaplana Grosso
JKJolle Kirpensteijn
Jolle Kirpensteijn
SNSebastiaan A. van Nimwegen
Sebastiaan A. van Nimwegen
Objectives: To determine 1) the sensitivity of contrast-enhanced CT (CECT) for detection of primary canine insulinomas and metastases 2) the sensitivity of CECT to locate canine insulinomas within the pancreas and 3) the CECT attenuation pattern of canine insulinomas and post-contrast phase in which insulinomas have the best visibility. Methods: A retrospective review was performed of the medical records of 27 canine insulinoma patients. Simultaneous occurrence of blood glucose < 3.5 mmol/L (reference interval: 4.2–5.8 mmol/L) and plasma insulin > 10 mIU/L (reference interval: 1.4–24.5 mIU/L) were considered diagnostic for insulinoma. The dogs had a mean age of 9.0 ± 1.7 (SD) years and comprised 11 males and 17 females. Results: Using CECT-scans, 26/27 insulinomas were successfully detected. However, CECT-scans predicted the correct location of insulinomas within the pancreas in only 14/27 dogs. In 9/13 inaccurately located insulinoma cases, the location error was major. There was no significant difference between triple, double and single-phase CECT-scans with location accuracies of 54%, 50% and 50%, respectively. Also, there was no specific post-contrast phase in which insulinomas could be visualised best. Detection of lymph node metastases with CECT-scans had a sensitivity of 67% (10/15 lymph node metastases). Detection of liver metastases had a sensitivity of 75% (6/8 liver metastases). This study highlights that major location errors mainly occurred if single- or double-phase CECT-scans were used (6/9 cases). Conclusion: It is suggested that triple-phase CECT-scans have superior outcome over single- or double-phase CECT-scans in pre-operative imaging of canine insulinomas.

1 July 2014 in The Veterinary Journal
Verified
Journal Article
Closed access
Floryne O. BuishandFloryne O. Buishand
Floryne O. Buishand
JVJudith Visser
Judith Visser
MKMarja Kik
Marja Kik
AGAndrea Gröne
Andrea Gröne
RKRebekah I. Keesler
Rebekah I. Keesler
JKJolle Kirpensteijn
Jolle Kirpensteijn

6 April 2016 in Stem Cells and Development
Verified
Journal Article
Closed access
Floryne O. BuishandFloryne O. Buishand
Floryne O. Buishand
GAGer J.A. Arkesteijn
Ger J.A. Arkesteijn
LFLaurien R. Feenstra
Laurien R. Feenstra
COClaire W.D. Oorsprong
Claire W.D. Oorsprong
MMMargriet Mestemaker
Margriet Mestemaker
JMJan Mol
Jan Mol
The long-term prognosis after surgical resection of malignant insulinoma (INS) is poor. Novel adjuvant therapies, specifically targeting cancer stem cells (CSCs), are warranted. Therefore, the goal of this study was to characterize and target putative INS CSCs. Using fluorescence-activated cell sorting, human INS cell line CM and pancreatic carcinoid cell line BON1 were screened for the presence of stem cell-associated markers. CD90, CD166, and GD2 were identified as potential CSC markers. Only CD90 + INS cells had an increased tumor-initiating potential in athymic nude mice. Anti-CD90 monoclonal antibodies decreased the viability and metastatic potential of injected cells in a zebrafish embryo INS xenograft model. Primary INS stained positive for CD90 by immunohistochemistry, however also intratumoral fibroblasts and vascular endothelium showed positive staining. The results of this study suggest that anti-CD90 monoclonals form a potential novel adjuvant therapeutic modality by targeting either INS cells directly, or by targeting the INS microenvironment.

1 August 2013 in The Veterinary Journal
Verified
Journal Article
Closed access
Floryne O. BuishandFloryne O. Buishand
Floryne O. Buishand
JKJolle Kirpensteijn
Jolle Kirpensteijn
AJAlexandra A. Jaarsma
Alexandra A. Jaarsma
ESErnst-Jan M. Speel
Ernst-Jan M. Speel
MKMarja Kik
Marja Kik
JMJan A. Mol
Jan A. Mol

14 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYlenia Capodanno
Ylenia Capodanno
Floryne O. BuishandFloryne O. Buishand
Floryne O. Buishand
LPL. Y. Pang
L. Y. Pang
JKJ. Kirpensteijn
J. Kirpensteijn
JMJ. A. Mol
J. A. Mol
DAD. J. Argyle
D. J. Argyle
Insulinomas (INS) are the most common human and canine functioning pancreatic neuroendocrine tumours. The long-term prognosis for malignant INS is poor, because micrometastases are frequently missed during surgery. As human and canine malignant INS share clinical and histopathological features, dogs have been proposed as models for INS research. Using RNA-sequencing, we conducted a pilot study to better understand the underlying molecular mechanisms of canine INS. Normal canine pancreas and lymph node control tissues were compared with primary INS and INS-metastatic lymph nodes, revealing more than 3,000 genes differentially expressed in normal pancreas compared to primary INS. Only 164 genes were differentially expressed between primary INS and INS-metastatic lymph nodes. Hierarchical clustering analysis demonstrated similar genetic profiles in normal pancreas and early clinical stage primary INS, whereas late clinical stage primary INS resembled the genetic profile of INS-metastatic lymph nodes. These findings suggest that markers of malignant behaviour could be identified at the primary site of the disease. Finally, using the REACTOME pathways database, we revealed that an active collagen metabolism, extracellular matrix remodelling, beta-cell differentiation and non-beta-cell trans-differentiation might cause disease progression and hyperinsulinism in INS, identifying major pathways worthy of future research in this currently poorly controlled disease.